Showing 13 of 13 results

I+Solutions
This presentation introduces Medexis eLMIS solution and a case study from Burundi.
Richard Mihigo, Alain Poy, Jethro Chakauya, Abubacar N’Diaye, Bernard Ntsama, Messeret Eshetu Shibeshi, Richard Luce, Balcha Girma Masresha
This study reviews the administrative routine immunization data from 15 African countries for the period from January 2018 to June 2020 to analyze the trends in the monthly number of children...
I+Solutions
This presentation introduces Medexis eLMIS solution and a case study from Burundi.
Home-based record (HBR) for Burundi circa 2010
Home-based record (HBR) for Burundi circa 2013
Mable Carole Tevi-Benissan et al.
Background Significant progress has been made to increase access to vaccines in Africa since the 1974 launch of the Expanded Programme on Immunization (EPI). Successes include the introduction of...
Corey KC & Noymer A
Using a mathematical model with realistic demography, we analyze a large outbreak of measles in Muyinga sector in rural Burundi in 1988-1989. We generate simulated epidemic curves and age × time...
Catherine Bruckner & Francesco Checchi
Fragile states are home to a sixth of the world\'s population, and their populations are particularly vulnerable to infectious disease outbreaks. Timely surveillance and control are essential to...
World Health Organization (WHO)
This report highlights the achievements made in expanding access to vaccines in Africa and discusses some of the remaining challenges to achieving universal access to vaccines. The timing of this...
World Health Organization (WHO)
This report, prepared by the Secretariat for the Decade of Vaccines Global Vaccine Action Plan, serves as the basis for the independent review. As was the case in 2013 and 2014, this report reviews...
Kathleen Tiffay et al.
The development, through a public–private partnership, of a safe, effective, and affordable vaccine for sub-Saharan Africa, PsA-TT, offers a new paradigm for the development of vaccines...
M. Teresa Aguado et al.
In June 2001, BMGF awarded a grant of US$70 million to create the Meningitis Vaccine Project (MVP) as a partnership between PATH and WHO, with the specific goal of developing an affordable MenA...